Commonwealth Equity Services
NAGE

Commonwealth Equity Services’s Niagen Bioscience NAGE Stock Holding History

Commonwealth Equity Services’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,022
Closed -$74K – 2950
2019
Q3 		$74K Hold
19,022
– – ﹤0.01% 2713
2019
Q2 		$88K Hold
19,022
– – ﹤0.01% 2644
2019
Q1 		$79K Hold
19,022
– – ﹤0.01% 2630
2018
Q4 		$65K Buy
19,022
+2,655
+16% +$9.23K ﹤0.01% 2547
2018
Q3 		$70K Buy
+16,367
New +$70.4K ﹤0.01% 2675
2017
Q2 		– Sell
-10,002
Closed -$27K – 2566
2017
Q1 		$27K Buy
+10,002
New +$28.4K ﹤0.01% 2361

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MFCM
Mercator Fund (Cayman Master) New York $125M AUM
SA
Sycale Advisors New York $201M AUM 2.35% 1-Year Est. Return

Commonwealth Equity Services's NAGE Position: Q4 2019 in Review

Commonwealth Equity Services sold out of Niagen Bioscience (NAGE) in Q4 2019, closing a stake of 19,022 shares — an estimated $74K sold.

Commonwealth Equity Services first reported a position in NAGE in Q1 2017 and held it in 6 quarters. The position peaked at $88K in Q2 2019. 65 funds tracked by Wall St. Rank hold NAGE as of Q4 2019.

  • Commonwealth Equity Services reported no remaining Niagen Bioscience position as of Q4 2019 after selling out during the quarter.
  • Commonwealth Equity Services sold 19,022 Niagen Bioscience shares in Q4 2019, an estimated $74K.
  • Commonwealth Equity Services first reported a position in Niagen Bioscience in Q1 2017 and held it in 6 quarters.
  • Commonwealth Equity Services's Niagen Bioscience position peaked at $88K in Q2 2019.
  • 65 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2019.

Based on Commonwealth Equity Services's 13F filing for Q4 2019, filed 5 Feb 2020.